Anlon Healthcare Ltd (AHCL) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management reaffirmed FY28 revenue guidance of INR 650-700 crore, primarily driven by its INR 130 crore capex for a 1,200 MTPA expansion.
- Commercial supply for the first of three innovator CDMO molecules is now expected in late Q3 or early Q4 FY27, a slight delay.
- The company's sustainable consolidated EBITDA margin is guided at 23-25%, a blend of high-margin pharma and lower-margin chemical business from its new subsidiaries.
Performance Overview
- The company has undergone significant strategic transformation, expanding into a group of five entities covering the full pharmaceutical value chain.
- Installed manufacturing capacity has increased to approximately 1900-2000 metric tons per annum, a substantial jump from the parent company's 400 metric tons.
- EBITDA margins showed strong sequential recovery in Q2 FY27, improving by over 600 basis points to 23.9% after a dip in the previous quarter.
- The company is making progress on key CDMO contracts, with commercial supplies for one molecule expected to start in late Q3 or early Q4 FY27.
- Revenue for the first half of FY27 has already surpassed the total revenue for the entire fiscal year of FY26, indicating strong growth momentum.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.